PRPH / ProPhase Labs Discloses 8.4% Position in LTRN / Lantern Pharma After Q3 Results

ProPhase Labs, Inc. (NASDAQ:PRPH ) Q2 2023 Earnings Conference Call August 10, 2023 11:00 AM ET Company Participants Ted Karkus - Chairman and CEO Con more_horizontal

Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) Conference Call and Webcast Details Management will host a confe more_horizontal

GARDEN CITY, NY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnost more_horizontal

ProPhase Labs thrived in the Covid era and then wisely used the gains to invest in new testing capabilities including whole genome sequencing and a ne more_horizontal

ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might n more_horizontal

ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might h more_horizontal

Medical diagnostic and testing concern ProPhase Labs, Inc. gets put in the spotlight today. ProPhase Labs, Inc. has seen huge revenue growth from Covi more_horizontal

GARDEN CITY, NY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and bio more_horizontal